ORIC Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
ORIC Pharmaceuticals, Inc. filed a Form 8-K on March 21, 2022, under Item 2.02 to announce financial results for the quarter and full year ended December 31, 2021. The filing concerns a clinical-stage pharmaceutical company; the provided filing text does not include further business or product detail.
Financial results and liquidity
The filing states that a press release announcing quarterly and full-year 2021 financial results was issued and furnished as Exhibit 99.1. The provided text does not include clear values for revenue, net income or loss, cash flow, margins, debt, cash, investments, liquidity, operating expenses, or research and development expenses.
Material changes versus the prior comparable period
The filing text does not provide a clear comparison with the prior quarter or prior year.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risk updates, contingencies, or unusual items are included in the provided Form 8-K text. These matters may be addressed in the referenced Exhibit 99.1 press release, which is not included in the supplied content.
Important facts to verify
- Obtain and review Exhibit 99.1 for the reported fourth-quarter and full-year 2021 financial metrics.
- Verify year-over-year changes in operating expenses, net loss, cash burn, and cash and investments.
- Confirm management’s stated cash runway, financing plans, clinical-development priorities, and any forward-looking guidance.
- Note that the financial information and exhibit were furnished under Items 2.02 and 9.01 and are not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly incorporated by reference.